99.4% PURITY LOT VL-2980-A KPV
An anti-inflammatory tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment α-MSH(11-13), supplied as a 5 mg lyophilized vial for research into melanocortin-pathway signaling, NF-κB modulation, and gut-inflammation models.
An anti-inflammatory tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment α-MSH(11-13), supplied as a 10 mg lyophilized vial for research into melanocortin-pathway signaling, NF-κB modulation, and gut-inflammation models.
- 1 × KPV 5mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
- 1 × KPV 10mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
About this compound
An anti-inflammatory tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment α-MSH(11-13), supplied as a 5 mg lyophilized vial for research into melanocortin-pathway signaling, NF-κB modulation, and gut-inflammation models.
- 5 mg lyophilized peptide per vial
- Tripeptide Lys-Pro-Val, α-MSH(11-13) C-terminal fragment
- Synthetic peptide, ≥99% purity
- Studied for anti-inflammatory activity via the melanocortin pathway
An anti-inflammatory tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment α-MSH(11-13), supplied as a 10 mg lyophilized vial for research into melanocortin-pathway signaling, NF-κB modulation, and gut-inflammation models.
- 10 mg lyophilized peptide per vial
- Tripeptide Lys-Pro-Val, α-MSH(11-13) C-terminal fragment
- Synthetic peptide, ≥99% purity
- Studied for anti-inflammatory activity via the melanocortin pathway
Why the lot matters
- Synthesized and tested per lot, never as a production-run average
- Certificate of Analysis published before the lot goes on sale
- Independent lab, contractually separate from manufacturing
What "research use only" means
This product is sold exclusively for in-vitro laboratory research. It is not evaluated by any medicines agency and is not intended for human or animal administration, diagnosis, treatment, or prevention of disease.
Technical data
Technical data
Current lot snapshot
Shipping
Reported use in research
KPV is investigated as an anti-inflammatory tripeptide derived from the C-terminal region of α-melanocyte-stimulating hormone (α-MSH). In preclinical models, research focuses on its ability to modulate the melanocortin signaling pathway and to dampen pro-inflammatory transcriptional programs. Studies examine how the peptide may interfere with nuclear factor-kappa B (NF-κB) activation and downstream cytokine production in cultured cells. Because it lacks the pigmentary region of the parent hormone, KPV is studied as a tool for isolating anti-inflammatory melanocortin activity from receptor-mediated pigmentation. Additional research explores its uptake by intestinal epithelial cells through peptide transporters as a model of localized mucosal signaling.
Reported findings
Research reports that KPV can reduce markers of inflammation in cellular assays exposed to pro-inflammatory stimuli. In animal research models of colitis, published studies describe attenuated tissue inflammation and reduced infiltration of immune cells following administration of the peptide. Investigators have observed decreased expression of inflammatory cytokines associated with NF-κB signaling in these models. Some reports also note that luminal delivery of KPV in rodent gut-inflammation models is associated with localized activity at the intestinal mucosa. These observations are confined to laboratory and preclinical research contexts and do not establish any effect in humans.
Handling & safety
The safety profile of KPV has not been completely characterized and no comprehensive toxicological data are available for this research compound. It should be handled only by qualified personnel trained in laboratory practices and using appropriate personal protective equipment. This material is supplied strictly for in-vitro and preclinical research use and is not for human or veterinary use. Store, handle, and dispose of the peptide in accordance with institutional safety guidelines and applicable regulations.
Reconstitution
Recommended ratio
- 1 mL of bacteriostatic water per 10 mg vial
- Equivalent to 10 mg/mL (i.e. 1 mg per 10 units on a 100 U insulin syringe)
- Remove the plastic flip-off lid from the vial.
- Disinfect the rubber stoppers with alcohol wipes.
- Inject the diluent slowly down the inner wall of the vial to avoid foaming.
- Gently swirl the vial (never shake). Let it dissolve for about 10 minutes.
Storage
Unopened / before reconstitution
- Store at a stable temperature.
- Stable for 24 months.
- For long-term storage (2+ years), store at -20 °C.
Reconstituted solution
- Must be kept refrigerated.
- Avoid exposure to light and excessive heat.
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 342.4 g/mol | PASS |
| Purity | HPLC (area %) | 99.4% | PASS |
| Net peptide content | Gravimetric | 4.99 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 342.4 g/mol | PASS |
| Purity | HPLC (area %) | 99.5% | PASS |
| Net peptide content | Gravimetric | 4.99 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 342.4 g/mol | PASS |
| Purity | HPLC (area %) | 99.6% | PASS |
| Net peptide content | Gravimetric | 10.00 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 342.4 g/mol | PASS |
| Purity | HPLC (area %) | 99.7% | PASS |
| Net peptide content | Gravimetric | 9.99 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2980-A | Jul 2026 | 99.4% | TR-88282 | Active | |
| VL-2999-B | May 2026 | 99.5% | TR-88215 | Sold out |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2610-A | Jul 2026 | 99.6% | TR-88056 | Active | |
| VL-2629-B | May 2026 | 99.7% | TR-88141 | Sold out |
